Equities research analysts expect Dyadic International, Inc. (NASDAQ:DYAI – Get Rating) to post earnings per share (EPS) of ($0.09) for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Dyadic International’s earnings. The lowest EPS estimate is ($0.14) and the highest is ($0.03). The firm is expected to announce its next earnings results after the market closes on Monday, January 1st.
On average, analysts expect that Dyadic International will report full-year earnings of ($0.27) per share for the current financial year, with EPS estimates ranging from ($0.39) to ($0.12). For the next year, analysts expect that the firm will post earnings of ($0.01) per share, with EPS estimates ranging from ($0.32) to $0.38. Zacks’ EPS averages are a mean average based on a survey of research firms that cover Dyadic International.
Dyadic International (NASDAQ:DYAI – Get Rating) last issued its quarterly earnings results on Tuesday, March 29th. The biotechnology company reported ($0.15) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.11). Dyadic International had a negative net margin of 543.68% and a negative return on equity of 58.65%. The business had revenue of $0.31 million during the quarter, compared to analyst estimates of $5.63 million.
Shares of Dyadic International stock traded up $0.04 on Tuesday, hitting $1.89. 229 shares of the company traded hands, compared to its average volume of 64,458. The stock’s 50-day moving average is $2.88. Dyadic International has a 12-month low of $1.74 and a 12-month high of $6.89.
Several institutional investors have recently bought and sold shares of the stock. Royal Bank of Canada increased its holdings in Dyadic International by 77.9% during the 2nd quarter. Royal Bank of Canada now owns 6,969 shares of the biotechnology company’s stock valued at $25,000 after purchasing an additional 3,051 shares in the last quarter. Teramo Advisors LLC bought a new stake in shares of Dyadic International during the fourth quarter worth $45,000. Morgan Stanley increased its stake in shares of Dyadic International by 1,167.3% in the second quarter. Morgan Stanley now owns 13,991 shares of the biotechnology company’s stock valued at $51,000 after buying an additional 12,887 shares in the last quarter. Dimensional Fund Advisors LP bought a new position in shares of Dyadic International in the third quarter valued at about $68,000. Finally, Commonwealth Equity Services LLC lifted its position in Dyadic International by 37.6% during the 1st quarter. Commonwealth Equity Services LLC now owns 28,018 shares of the biotechnology company’s stock worth $84,000 after buying an additional 7,650 shares in the last quarter. Institutional investors and hedge funds own 26.12% of the company’s stock.
Dyadic International Company Profile (Get Rating)
Dyadic International, Inc, a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States. The company utilizes its patented and proprietary C1 platform and other technologies to conduct research, development, and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus like particles and antigens, monoclonal antibodies, bi/tri-specific antibodies, fab antibody fragments, Fc-fusion proteins, biosimilars and/or biobetters, and other therapeutic enzymes and proteins.
- Get a free copy of the StockNews.com research report on Dyadic International (DYAI)
- If PetMeds Is A Good Buy There Will Be A Better Signal
- Insiders Buy Occidental Petroleum Ahead Of Q1 Earnings
- High-Yield Deep-Value LCI Industries Exceeds All Expectations
- Shopify (NYSE: SHOP) Approaches Key Support Level
- The Low In Lordstown Motors May Not Be The Last
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Dyadic International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dyadic International and related companies with MarketBeat.com's FREE daily email newsletter.